1Kempen JH, Ocolmain BJ, Leske MC, et al.The prevalence of diabetic retinopathy among adrtlts in the United States [J ]. Arch Ophthalmol, 2004, 122(4) : 552-563.
8Kunt T, Schneider S, PfiitznerA, et al.The effect of human proinsulin C-peptide on erythrocyte deformability in pa- tients with type 1 diabetes mellilus [J].Diabetologia, 1999, 42 (4) :465 -471.
9Ohtomo Y, Apefia A, Sahlgren B, et al.C-peptide stimulates rat renal Na+-K+-ATPase activity in synergism with neuro- peptide Y [ J ].Diabetologia, 1996,39 (2): 199-205.
10Tsimaratos M, Roger F, Chabardes D, et al.C-peptide stim- ulates Na+-K+-ATPase activity via PKC alpha in rat medul- lary thick ascending limb [J].Diabetologia, 2003,46 ( 1 ): 124-131.
4Kempen JH,OColmain BJ,Leske MC,et al. The prevalence of diabeticretinopathy among adults in the United States [ J]. Arch Ophthalmol,2004,122(4):552 -563.
5Kowluru RA, Zhong Q. Beyond AREDS: is there a place for antioxidanttherapy in the prevention/treatment of eye disease [ J] . Invest Ophthal-mol Vis Sci, 2011,52(12) ;8665 -8671.
6Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men andwomen in China[J]. N Engl J Med, 2010,362(12) :1090-1101.
7Porta M, Allione A. Current approaches and perspectives in the medical treat-ment of diabetic retinopathy [J]. Hiarmacol Iher,2004,103(2) :167 -177.
8Takao T,Ide T,Yanagisawa H, et al. The effect of fasting plasma glu-cose variability on the risk of retinopathy in type 2 diabetic patients : ret-rospectivelong - term follow - up [ J]. Diabetes Res Clin Pract, 2010,89(3) :296-302.
10Bergman PB, Moravski CJ, Edmondson SR, et al. Expression of the IGF system in normal and diabetic transgenic (mRen-2)27 rat eye [ J ]. Invest Ophthalmol Vis Sci ,2005,46 (8) :2708-2715.
